Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 680 across all filing types
Latest filing 2021-09-10 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges notifying them about the schedule of upcoming analyst and institutional investor meetings. It references compliance with SEBI regulations and provides dates and types of meetings. There is no financial data, report content, or detailed presentation included. The document is an announcement of meetings rather than a report or transcript. Therefore, it fits best under Investor Presentation (IP) as it relates to investor communications, but since it only announces the schedule and does not contain the presentation itself, it is more appropriate to classify it as Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-09-10 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation' and is addressed as an attachment pursuant to a regulatory disclosure requirement. It contains detailed slides and information about the company's industry trends, business model, COVID-19 impact, growth strategy, and key performance indicators. The content is typical of a presentation prepared for investors at a conference or event, focusing on financials, strategy, and market position. There is no indication that this is a formal report like an Annual Report (10-K) or Interim Report (IR), nor is it a brief announcement or certification. The document length (13,079 characters) supports a detailed presentation rather than a short announcement. Therefore, the appropriate classification is Investor Presentation (IP).
2021-09-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the schedule of upcoming analyst and institutional investor meetings. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which pertains to disclosure of material events and information. The content is an announcement of planned investor conferences and meetings, not a financial report, earnings release, or detailed presentation. The document is short (1511 characters) and serves as an informational notice about investor meetings. This fits the category of Investor Presentation (IP) as it relates to investor communications and meetings, but since it is only a schedule notice and not the presentation itself, it is best classified as Regulatory Filings (RNS) which is the fallback for miscellaneous regulatory announcements that do not fit other categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-09-06 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the schedule of analyst and institutional investor meetings. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which pertains to disclosure of material events and information. The content is about announcing upcoming investor meetings, not a financial report, earnings release, or detailed presentation. The document length is short (1384 characters) and it serves as an announcement of scheduled meetings rather than the meetings' content or transcript. Therefore, it fits best under Investor Presentation (IP) category as it relates to investor communications, but since it only announces the schedule and does not provide detailed presentation materials, it is more appropriate to classify it as a Regulatory Filing (RNS) which is a fallback for miscellaneous regulatory announcements and disclosures that do not fit other categories.
2021-09-03 English
Shareholders meeting
AGM Information Classification · 100% confidence The document is a transcript of the 43rd Annual General Meeting (AGM) of Gland Pharma Limited held on August 26, 2021. It includes detailed proceedings of the meeting, introductions of board members and management, discussions on company performance, and shareholder participation instructions. The text explicitly states it is a transcript of the AGM, which aligns with the definition of AGM Information (AGM-R). The document is lengthy (15,000 characters) and contains the full text of the meeting, not just an announcement or summary. Therefore, it is not a report publication announcement or a regulatory filing. The presence of detailed meeting dialogue and management speeches confirms it is an AGM transcript.
2021-09-02 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchanges about the schedule of analyst and institutional investor meetings. It references compliance with SEBI regulations and provides a table with meeting details. There is no financial data, report content, or detailed presentation included. The document is an announcement of upcoming meetings rather than a report or transcript of the meetings themselves. Given the nature and length of the document, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-08-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.